Published in Blood Weekly, June 30th, 1997
CellPro Inc., Seattle, Washington, announced preliminary results of its Phase III clinical trial using the Ceprate SC Stem Cell Concentration System to select peripheral blood stem cells from patients with multiple myeloma. These results were presented at the VI International Workshop on Multiple Myeloma, held in Boston, Massachusetts, during June 1997.
The open-label, randomized clinical trial was initiated in January 1995 at 15 sites in the United States and Canada and enrolled 134 patients eligible for a peripheral blood...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.